| Annapoorna H Murthy, MD | |
|
290 Central Way, Kirkland, WA 98033-6104 | |
| (425) 635-6470 | |
| (425) 635-6499 |
| Full Name | Annapoorna H Murthy |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 290 Central Way, Kirkland, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275884405 | NPI | - | NPPES |
| MD60300162 | Other | WA | MD LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD60300162 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Overlake Hospital Medical Center | Bellevue, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Overlake Medical Clinics Llc | 7012808827 | 350 |
News Archive
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.
If you missed your morning coffee and now you have a headache and difficulty concentrating, you might be able to blame it on caffeine withdrawal.
Proposed cuts to the Medicare payment rates for drugs that hospitals acquire under the 340B Drug Pricing Program, if enacted, could have devastating consequences for the low-income and uninsured patients that receive care from the nation's safety net hospitals, according to ASHP.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
› Verified 2 days ago
| Entity Name | Sea-mar Community Health Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811051170 PECOS PAC ID: 7315831161 Enrollment ID: O20040211001210 |
News Archive
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.
If you missed your morning coffee and now you have a headache and difficulty concentrating, you might be able to blame it on caffeine withdrawal.
Proposed cuts to the Medicare payment rates for drugs that hospitals acquire under the 340B Drug Pricing Program, if enacted, could have devastating consequences for the low-income and uninsured patients that receive care from the nation's safety net hospitals, according to ASHP.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
› Verified 2 days ago
| Entity Name | Overlake Medical Clinics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801828421 PECOS PAC ID: 7012808827 Enrollment ID: O20040322001533 |
News Archive
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.
If you missed your morning coffee and now you have a headache and difficulty concentrating, you might be able to blame it on caffeine withdrawal.
Proposed cuts to the Medicare payment rates for drugs that hospitals acquire under the 340B Drug Pricing Program, if enacted, could have devastating consequences for the low-income and uninsured patients that receive care from the nation's safety net hospitals, according to ASHP.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Annapoorna H Murthy, MD Po Box 34703, Seattle, WA 98124-1703 Ph: (206) 764-3335 | Annapoorna H Murthy, MD 290 Central Way, Kirkland, WA 98033-6104 Ph: (425) 635-6470 |
News Archive
AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.
If you missed your morning coffee and now you have a headache and difficulty concentrating, you might be able to blame it on caffeine withdrawal.
Proposed cuts to the Medicare payment rates for drugs that hospitals acquire under the 340B Drug Pricing Program, if enacted, could have devastating consequences for the low-income and uninsured patients that receive care from the nation's safety net hospitals, according to ASHP.
Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48.
Idera Pharmaceuticals, Inc. presented data on the evaluation of a Toll-like receptor (TLR) antagonist in a preclinical hyperlipidemia model today at the Keystone Symposia conference "Advances in Molecular Mechanisms of Atherosclerosis" being held in Banff, Alberta, Canada. Idera's proprietary TLR antagonists have dual activity for both TLR7 and TLR9, and present a potentially innovative approach for the treatment of certain autoimmune diseases.
› Verified 2 days ago
Rubbiya Asim Bhatti, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11800 Ne 128th St Ste 300, Kirkland, WA 98034 Phone: 425-814-5100 Fax: 425-814-5103 | |
Edward Sungwon Lee, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11800 Ne 128th St Fl 5, Kirkland, WA 98034 Phone: 425-899-5200 Fax: 425-899-5204 | |
Sarah Chase Abbot, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12710 Totem Lake Blvd Ne, Kirkland, WA 98034 Phone: 425-821-4040 Fax: 425-820-5060 | |
Reza Tabibi, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 11521 Ne 128th St Ste 100, Kirkland, WA 98034 Phone: 425-899-6800 Fax: 425-899-6808 | |
Larry E Nacht, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 12710 Totem Lake Blvd Ne, Kirkland, WA 98034 Phone: 425-821-4040 | |
David Steven Paplow, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 13014 120th Ave Ne, Kirkland, WA 98034 Phone: 425-821-8004 | |
Dr. Lane N Ertugay, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 12675 120th Ave Ne Ste 193, Kirkland, WA 98034 Phone: 888-663-6331 |